Following the agreement in November 2022, the collaboration yielded an AI-facilitated lead with first-in-class (FIC) potential against an undruggable transcription factor target for treating oncology diseases, enhanced by Insilico Medicine’s AI platform (IMAGE)

InSilico Medicine

Following the agreement in November 2022, the collaboration yielded an AI-facilitated lead with first-in-class (FIC) potential against an undruggable transcription factor target for treating oncology diseases, enhanced by Insilico Medicine’s AI platform

Caption

Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be “undruggable”. Together, the teams addressed this druggability challenge through further lead optimization based on novel scaffolds generated by Chemistry42, the highly flexible generative AI engine for drug design and discovery.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.